Online citations, reference lists, and bibliographies.

Nanobiomaterials’ Applications In Neurodegenerative Diseases

Daniela Silva Adaya, Lucinda Aguirre-Cruz, Jorge Guevara, Emma Ortiz-Islas
Published 2017 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
The blood–brain barrier is the interface between the blood and brain, impeding the passage of most circulating cells and molecules, protecting the latter from foreign substances, and maintaining central nervous system homeostasis. However, its restrictive nature constitutes an obstacle, preventing therapeutic drugs from entering the brain. Usually, a large systemic dose is required to achieve pharmacological therapeutic levels in the brain, leading to adverse effects in the body. As a consequence, various strategies are being developed to enhance the amount and concentration of therapeutic compounds in the brain. One such tool is nanotechnology, in which nanostructures that are 1–100 nm are designed to deliver drugs to the brain. In this review, we examine many nanotechnology-based approaches to the treatment of neurodegenerative diseases. The review begins with a brief history of nanotechnology, followed by a discussion of its definition, the properties of most reported nanomaterials, their biocompatibility, the mechanisms of cell–material interactions, and the current status of nanotechnology in treating Alzheimer’s, Parkinson’s diseases, and amyotrophic lateral sclerosis. Of all strategies to deliver drug to the brain that are used in nanotechnology, drug release systems are the most frequently reported.
This paper references
10.1111/j.1755-5949.2012.00340.x
Tight junction in blood-brain barrier: an overview of structure, regulation, and regulator substances.
Wei-ye Liu (2012)
10.1016/j.addr.2012.09.015
Nanoparticulate systems for brain delivery of drugs.
Joerg Prof Dr Kreuter (2001)
10.1002/anie.201007824
Inhibition of amyloid peptide fibrillation by inorganic nanoparticles: functional similarities with proteins.
Seong Il Yoo (2011)
10.1016/j.neulet.2009.03.064
Nanoparticle–chelator conjugates as inhibitors of amyloid-β aggregation and neurotoxicity: A novel therapeutic approach for Alzheimer disease
Gang Liu (2009)
10.17925/ENR.2006.00.02.78
Memantine in Moderate-to-severe Alzheimer's Disease
Matthias W Riepe (2006)
10.1016/j.msec.2015.01.073
Biodegradation-tunable mesoporous silica nanorods for controlled drug delivery.
Sung Bum Park (2015)
10.1016/j.brainres.2008.01.039
Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease
Barnabas Wilson (2008)
10.1002/jbm.a.35504
Silica-based mesoporous nanobiomaterials as promoter of bone regeneration process.
Nasrin Shadjou (2015)
10.1073/pnas.0504926102
Organically modified silica nanoparticles: a nonviral vector for in vivo gene delivery and expression in the brain.
Dhruba J. Bharali (2005)
10.1016/S0165-6147(00)01638-2
Gene therapy to the rescue in Parkinson's disease.
Allen S. Mandir (2001)
10.1002/jbm.a.34031
Chitosan-based nanoparticles as a sustained protein release carrier for tissue engineering applications.
Yaping Hou (2012)
10.1007/s11051-012-1323-5
A facile route to synthesize nanogels doped with silver nanoparticles
M. Carme Coll Ferrer (2012)
10.18388/abp.2001_5127
Dendrimers: properties and applications.
Barbara Klajnert (2001)
10.1021/ja800079j
Synthesis of two mirror image 4-helix junctions derived from glycerol nucleic acid.
Richard S. Zhang (2008)
10.1023/A:1010931127745
Long-Circulating PEGylated Polycyanoacrylate Nanoparticles as New Drug Carrier for Brain Delivery
Pilar Blanco Calvo (2004)
10.1021/nl035193d
Chemically Functionalized Carbon Nanotubes as Substrates for Neuronal Growth.
Hui Hu (2004)
10.1016/j.maturitas.2011.12.015
Nanotechnology for neurodegenerative disorders.
Francesca Re (2012)
10.1073/pnas.94.17.9434
Carboxyfullerenes as neuroprotective agents.
Laura l. Dugan (1997)
10.1016/j.ejpb.2008.08.021
Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB).
Karsten Ulbrich (2009)
10.1016/j.bbagen.2010.04.007
Toxicology of engineered nanomaterials: focus on biocompatibility, biodistribution and biodegradation.
Andrea Kunzmann (2011)
10.1155/2009/815734
Review: biofunctionalized quantum dots in biology and medicine
Sonal Mazumder (2009)
Nanogelquantum dot hybrid NPs for live cell imaging
U Hasegawa (2005)
10.1021/bc900410q
gamma-Glutamyl PAMAM dendrimer as versatile precursor for dendrimer-based targeting devices.
Tomoya Uehara (2010)
10.1002/PPSC.201300173
Gold Nanocages as Effective Photothermal Transducers in Killing Highly Tumorigenic Cancer Cells
Aravind Kumar Rengan (2014)
10.1517/17460441.2012.722078
Advances in use of functionalized carbon nanotubes for drug design and discovery
Kewal K. Jain (2012)
10.1002/CHIN.200822266
Nanoscaling Laws of Magnetic Nanoparticles and Their Applicabilities in Biomedical Sciences
Young-Wook Jun (2008)
10.1007/s11095-007-9514-y
Solid Lipid Nanoparticles as Delivery Systems for Bromocriptine
Elisabetta Esposito (2007)
10.1517/14656566.2013.819344
New therapy options for amyotrophic lateral sclerosis
Paul H. Gordon (2013)
10.1038/354056a0
Helical microtubules of graphitic carbon
Sumio Iijima (1991)
10.1016/S0167-7799(97)01036-6
Biomedical applications of nanotechnology--implications for drug targeting and gene therapy.
Stanley Stewart Davis (1997)
10.1002/mds.20276
Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
Regina Katzenschlager (2005)
10.1016/S0024-3205(00)00470-7
Blockage of amyloid beta peptide-induced cytosolic free calcium by fullerenol-1, carboxylate C60 in PC12 cells.
Hui Ming Huang (2000)
10.1021/cn300048q
Carbon nanotubes: artificial nanomaterials to engineer single neurons and neuronal networks.
Alessandra Fabbro (2012)
10.1016/j.nano.2014.09.014
Mesoporous silica nanoparticles in drug delivery and biomedical applications.
Ying Wang (2015)
Interaction between amyloid beta-protein aggregates and membranes.
Atsuko Kakio (2004)
10.1016/j.ejpb.2004.07.009
Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases.
Zhengrong Cui (2005)
10.1016/j.biomaterials.2010.10.027
Curcumin-decorated nanoliposomes with very high affinity for amyloid-β1-42 peptide.
Spyridon D. Mourtas (2011)
10.1001/jama.2014.3654
Pharmacological treatment of Parkinson disease: a review.
Barbara S. Connolly (2014)
10.1117/1.JNP.7.073075
Supra gap excitation properties of differently confined PbS-nano structured materials studied with opto-impedance spectroscopy
Syed Abuthahir Ziaudeen (2013)
10.4103/0975-7406.94153
Synthesis of mesoporous silica nanoparticles and drug loading of poorly water soluble drug cyclosporin A
Abhijit Lodha (2012)
10.1021/BM700606Z
Cell-specific delivery of polymeric nanoparticles to carbohydrate-tagging cells.
Yasuhiko Iwasaki (2007)
10.1039/b815061c
A high sensitive and specific QDs FRET bioprobe for MNase.
Shan Huang (2008)
10.1016/j.jcis.2010.09.053
Nanoparticle carriers based on copolymers of poly(ε-caprolactone) and hyperbranched polymers for drug delivery.
Tiewei Wang (2011)
10.1111/j.1365-2125.2011.04134.x
New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs.
Salvatore Salomone (2012)
10.1016/j.colsurfb.2011.01.001
Improved GFP gene transfection mediated by polyamidoamine dendrimer-functionalized multi-walled carbon nanotubes with high biocompatibility.
Weiling Qin (2011)
10.1016/j.ejpb.2008.03.009
Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles.
Barnabas Wilson (2008)
10.1016/j.biomaterials.2010.03.048
Surface charge-mediated rapid hepatobiliary excretion of mesoporous silica nanoparticles.
Jeffrey S. Souris (2010)
Toxicity of NMs
S Sharifi (2012)
10.1016/j.nano.2006.11.008
The present and future of nanotechnology in human health care.
Sabuj Sahoo (2007)
10.1038/nbt872
The 'right' size in nanobiotechnology
George M. Whitesides (2003)
10.1016/j.jconrel.2008.10.010
Enhanced photodynamic cancer treatment by supramolecular nanocarriers charged with dendrimer phthalocyanine.
Nobuhiro Nishiyama (2009)
10.1016/j.jpsychires.2014.03.021
Humanistic burden in schizophrenia: a literature review.
Aurélie Millier (2014)
10.1021/acs.langmuir.5b01316
A Biodegradation Study of SBA-15 Microparticles in Simulated Body Fluid and in Vivo.
Youngjin Choi (2015)
10.4135/9781529719307
HIV and substance abuse.
A. Ashok Kumar (2012)
10.1002/adma.201401124
Core-shell-type magnetic mesoporous silica nanocomposites for bioimaging and therapeutic agent delivery.
Yao Wang (2015)
10.1002/jbm.a.35312
Potential efficacy of dopamine loaded-PVP/PAA nanogel in experimental models of Parkinsonism: possible disease modifying activity.
Engy Refaat Rashed (2015)
10.3109/10837450.2014.996900
Nanostructured lipid carriers as novel drug delivery system for lung cancer gene therapy
Yiqun Han (2016)
10.1186/1752-153X-7-11
Gold nanoparticles as efficient antimicrobial agents for Escherichia coli and Salmonella typhi
E. L. Lima (2013)
10.1016/j.jconrel.2012.03.026
Therapeutics, imaging and toxicity of nanomaterials in the central nervous system.
António Nunes (2012)
10.1016/j.jconrel.2011.11.031
Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers.
Jesse B. Wolinsky (2012)
10.1016/j.jconrel.2010.04.029
Spherical mesoporous silica nanoparticles for loading and release of the poorly water-soluble drug telmisartan.
Yonglong Zhang (2010)
10.1002/adma.201000262
Poly(methacrylic acid)-grafted carbon nanotube scaffolds enhance differentiation of hESCs into neuronal cells.
Tzu-I Chao (2010)
Albuminated PLGA NPs containing bevacizumab intended for ocular neovascularization treatment
V Reyhaneh (2015)
10.1016/J.MATLET.2014.10.010
Synthesis and characterization of Arabic gum capped gold nanoparticles for tumor-targeted drug delivery
Parvathi R. Devi (2015)
10.1016/J.MATCHEMPHYS.2014.02.039
Physicochemical characterization of functionalized-nanostructured-titania as a carrier of copper complexes for cancer treatment
Tessy Lopez (2014)
10.1016/S0304-3940(02)01399-X
Electron microscopic analysis of nanoparticles delivering thioflavin-T after intrahippocampal injection in mouse: implications for targeting β-amyloid in Alzheimer's disease
Wolfgang Härtig (2003)
10.1016/j.msec.2015.11.067
Polymeric nanoparticles for targeted drug delivery system for cancer therapy.
Farha Masood (2016)
10.1038/71889
Synthetic DNA delivery systems
Dan Luo (2000)
Inorganic NPs. engineering for biomedical applications
J Zhang (2014)
Recent developments in liposomes, microparticles and NPs for protein and peptide drug delivery
T Mei (2010)
Neuroinflammation in Alzheimer ’ s disease-A Review
Manju Bhaskar (2017)
10.1088/0022-3727/38/13/001
Quantum dots for lasers, amplifiers and computing
Dieter Bimberg (2005)
10.2217/nnm.09.67
Brain-targeted solid lipid nanoparticles containing riluzole: preparation, characterization and biodistribution.
Maria Luisa Bondì (2010)
10.1002/psc.570
Interaction between amyloid β-protein aggregates and membranes
Atsuko Kakio (2004)
10.1002/cmmi.1611
Solid silica nanoparticles: applications in molecular imaging.
Vahid Shirshahi (2015)
10.4314/AJB.V7I25.59701
Protein nanoparticle: A unique system as drug delivery vehicles
Mohsen Jahanshahi (2008)
10.1016/j.ymthe.2006.09.001
Neurotensin polyplex as an efficient carrier for delivering the human GDNF gene into nigral dopamine neurons of hemiparkinsonian rats.
J. A. González-Barrios (2006)
10.1017/S0033291713003243
The global burden of anxiety disorders in 2010.
Amanda J. Baxter (2014)
10.4103/2230-973X.160844
Mesoporous silica nanoparticles in target drug delivery system: A review
Charu Bharti (2015)
10.1007/s12031-002-0033-3
Slowing the progression of cognitive decline in alzheimer’s disease using mifepristone
Joseph K. Belanoff (2002)
10.1016/j.addr.2005.09.019
Dendrimer biocompatibility and toxicity.
Ruth Duncan (2005)
10.1002/chem.201501966
Mesoporous Silica Nanoparticles Decorated with Carbosilane Dendrons as New Non-viral Oligonucleotide Delivery Carriers.
Ángel Manu Martínez (2015)
10.2147/IJN.S83777
Carbon nanotubes and graphene as emerging candidates in neuroregeneration and neurodrug delivery
Agnes Aruna John (2015)
10.1049/iet-nbt.2013.0004
Application of silica nanoparticles in maize to enhance fungal resistance.
Rangaraj Suriyaprabha (2014)
10.1016/j.nano.2012.03.005
Dendrimers reduce toxicity of Aβ 1-28 peptide during aggregation and accelerate fibril formation.
Barbara Klajnert (2012)
Fullerene nanomaterial inhibit the allergic response
JJ Ryan (2007)
10.1016/j.bios.2012.06.049
Enhanced lateral flow immunoassay using gold nanoparticles loaded with enzymes.
Claudio Parolo (2013)
10.1177/1352458512453362
Bone health and multiple sclerosis
Ruth Dobson (2012)
10.2174/157016212802138814
Editorial: [Hot Topic HIV and Substance Abuse]
A. Bharath Kumar (2012)
10.1038/NPHOTON.2009.92
High-performance crosslinked colloidal quantum-dot light-emitting diodes
Kyung-Sang Cho (2009)
10.3109/10408444.2010.533152
Hazard identification of particulate matter on vasomotor dysfunction and progression of atherosclerosis
Peter Møller (2011)
10.1134/S0006297909100022
Dendrimers in gene transfection
Dmitry G. Shcharbin (2009)
10.1073/pnas.90.5.1635
Supramolecular chemistry.
William L. Jorgensen (1993)
10.1602/neurorx.2.1.129
Tyrosine hydroxylase replacement in experimental Parkinson’s disease with transvascular gene therapy
William M Pardridge (2005)
10.1016/j.peptides.2009.10.002
Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery
Mei Lin Tan (2010)
10.1002/CHIN.201348209
Colloidal quantum dot materials and devices: a quarter-century of advances
David Zhitomirsky (2013)
10.1001/archneur.64.1.137
Pathophysiology of motor complications in Parkinson disease: postsynaptic mechanisms are crucial.
Gurutz Linazasoro (2007)
10.3109/1061186X.2015.1020809
Nanotechnology-mediated nose to brain drug delivery for Parkinson's disease: a mini review
Abhijeet Kulkarni (2015)
10.1088/0957-4484/16/12/042
Irreversible blocking of ion channels using functionalized single-walled carbon nanotubes
Manish Chhowalla (2005)
Quantum size effect in three-dimensional microscopic semiconductor crystals
A. I. Ekimov (1981)
10.3109/1061186X.2011.595490
Chlorotoxin-modified stealth liposomes encapsulating levodopa for the targeting delivery against the Parkinson’s disease in the MPTP-induced mice model
Yu Xiang (2012)
10.1016/j.bbamem.2008.10.022
The blood-brain barrier in brain homeostasis and neurological diseases.
Nicolas Weiss (2009)
10.1021/nl025689f
Preparation of Nucleic Acid Functionalized Carbon Nanotube Arrays
Cattien V. Nguyen (2002)
10.1021/bm900266r
Interaction of nanoparticles with cells.
Volker Mailaender (2009)
10.1016/S1353-8020(00)00064-X
Fullerene-based antioxidants and neurodegenerative disorders.
Laura l. Dugan (2001)
10.1166/jnn.2007.330
Effects of hydrated forms of C60 fullerene on amyloid 1-peptide fibrillization in vitro and performance of the cognitive task.
I Ya Podolski (2007)
Biocompatibility and toxicity of NPs and nanotubes
X Li (2012)
10.1039/b915139g
Designing multifunctional quantum dots for bioimaging, detection, and drug delivery.
Pavel Zrazhevskiy (2010)
10.1039/C1JM11401H
Emerging functional nanomaterials for therapeutics
Xuejia Xue (2011)
10.1021/ar700121f
Nanoscaling laws of magnetic nanoparticles and their applicabilities in biomedical sciences.
Young-Wook Jun (2008)
10.1016/J.POLYMDEGRADSTAB.2008.04.012
Synthesis and degradation behavior of poly(ethyl cyanoacrylate)
Moon Gyu Han (2008)
10.1016/J.NANTOD.2008.10.009
Applications of nanomaterials inside cells
Jinhao Gao (2009)
10.3109/03639045.2010.539231
In vitro evaluation of idebenone-loaded solid lipid nanoparticles for drug delivery to the brain
Lucia Montenegro (2011)
10.1039/c2nr12083f
Manufacturing of inorganic nanomaterials: concepts and perspectives.
Alberto Gasparotto (2012)
10.1002/CHIN.201224275
Gold Nanoparticles in Biomedical Applications: Recent Advances and Perspectives
Lev A. Dykman (2012)
10.1021/bm2008636
Dense shell glycodendrimers as potential nontoxic anti-amyloidogenic agents in Alzheimer's disease. Amyloid-dendrimer aggregates morphology and cell toxicity.
Oxana Klementieva (2011)
10.1063/1.3676203
Facile synthesis and magnetic property of iron oxide/MCM-41 mesoporous silica nanospheres for targeted drug delivery
Le-Le Yu (2012)
10.1021/bc700184b
A macrophage-nanozyme delivery system for Parkinson's disease.
Elena V Batrakova (2007)
10.4172/2150-3494.1000061
Application of Nanoparticles of Ceramics, Peptides, Silicon, Carbon, and Diamonds in Tissue Engineering
Syed A. Jamal (2013)
10.1016/j.biomaterials.2005.05.027
Nano-C60 cytotoxicity is due to lipid peroxidation.
Christie M. Sayes (2005)
10.1080/13803395.2015.1073227
Parkinson’s disease dementia: Diagnostic criteria and risk factor review
Luiz Felipe R Vasconcellos (2015)
10.1021/la970801o
Preparation of Ag/SiO2 Nanosize Composites by a Reverse Micelle and Sol−Gel Technique
Tuo Li (1999)
10.1016/j.tibs.2005.01.007
From genes to machines: DNA nanomechanical devices.
Nadrian C. Seeman (2005)
10.1002/chin.200035237
Dendrimers as Fluorescent Sensors with Signal Amplification
Vincenzo Balzani (2000)
10.1126/science.254.5035.1183
Radical Reactions of C60
Paul J. Krusic (1991)
Biomater protein NPs for therapeutic protein delivery
L Herrera (2015)
10.1186/1556-276X-9-247
Dendrimers: synthesis, applications, and properties
Elham Abbasi (2014)
10.1176/appi.ajp.2013.12081046
The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease.
Oscar L. Lopez (2013)
10.1016/j.eurpsy.2011.06.001
Alzheimer's disease and co-morbidity: increased prevalence and possible risk factors of excess mortality in a naturalistic 7-year follow-up.
Reinhard Heun (2013)
Nanotechnologies for Neurodegenerative Diseases Study Group of the Basque , Potential applications of nanotechnologies to Parkinson ’ s disease ther
G Linazasoro (2008)
Scientific basis of nanotechnology , implications for the food sector and future trends
M. Rossia
10.1002/mabi.200800242
PAMAM dendrimers as potential agents against fibrillation of alpha-synuclein, a Parkinson's disease-related protein.
Agata Rekas (2009)
10.1111/j.1471-4159.2007.04591.x
In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques.
J. F. Poduslo (2007)
10.1074/jbc.M100252200
Cholesterol-dependent Formation of GM1 Ganglioside-bound Amyloid β-Protein, an Endogenous Seed for Alzheimer Amyloid*
Atsuko Kakio (2001)
10.1073/pnas.0701250104
Nucleation of protein fibrillation by nanoparticles
Sara Linse (2007)
10.1088/0957-4484/26/43/432001
An overview of synthetic strategies and current applications of gold nanorods in cancer treatment.
Prit Manish Lakhani (2015)
10.1016/j.addr.2009.01.004
Design and development of dendrimer photosensitizer-incorporated polymeric micelles for enhanced photodynamic therapy.
Nobuhiro Nishiyama (2009)
10.1016/j.nano.2014.12.014
Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases.
Howard E. Gendelman (2015)
10.1016/j.biomaterials.2008.04.023
On the mechanisms of biocompatibility.
David Williams (2008)
mifepristone) in the adjunctive treatment of Alzheimer’s disease
C DeBattista (2005)
Shape control of inorganic NPs from solution
A Wu (2016)
10.1021/am3028662
Quantum-dot-based photoelectrochemical sensors for chemical and biological detection.
Zhao Yue (2013)
10.1128/AAC.00809-06
Poly(d,l-Lactide-Coglycolide) Particles Containing Gentamicin: Pharmacokinetics and Pharmacodynamics in Brucella melitensis- Infected Mice
María Concepción Lecároz (2007)
10.1002/PI.4192
Study of pH/temperature dual stimuli‐responsive nanogels with interpenetrating polymer network structure
Xiaoyun Liu (2012)
10.1177/0885328215594479
Curcumin-loaded polymeric nanoparticles for enhanced anti-colorectal cancer applications
Panisa Udompornmongkol (2015)
10.1371/journal.pone.0032616
Curcumin Loaded-PLGA Nanoparticles Conjugated with Tet-1 Peptide for Potential Use in Alzheimer's Disease
Anila Mathew (2012)
10.1111/j.1460-9568.2007.06018.x
Neuroprotective effects of novel phosphatidylglycerol-based phospholipids in the 6-hydroxydopamine model of Parkinson's disease.
S Crotty (2008)
10.1016/j.ejpain.2009.07.006
Severe chronic pain is associated with increased 10 year mortality. A cohort record linkage study.
Nicola Torrance (2010)
10.1016/j.cis.2014.10.007
Sol-Gel processing of silica nanoparticles and their applications.
Lok Pratap Singh (2014)
10.1007/s11095-013-1156-7
Nanotechnology-Based Drug Delivery Systems for Targeting, Imaging and Diagnosis of Neurodegenerative Diseases
Sibel Bozdağ Pehlivan (2013)
10.3233/JAD-2005-7405
Nanosphere-mediated delivery of vitamin E increases its efficacy against oxidative stress resulting from exposure to amyloid beta.
Thomas B. Shea (2005)
10.1126/science.1093783
Selective Differentiation of Neural Progenitor Cells by High-Epitope Density Nanofibers
Gabriel Almeida Silva (2004)
10.1016/j.pneurobio.2009.05.002
Nanotechnological applications for the treatment of neurodegenerative disorders
Girish Modi (2009)
10.1002/IJCH.201300055
Gene Delivery by Liposomes
Mirjam M. Nordling-David (2013)
10.1016/J.TECHNOVATION.2012.01.003
The Future Of Nanotechnologies
Vincent Mangematin (2012)
10.1186/1743-8977-7-3
Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging
Sonu Bhaskar (2009)
10.1185/03007991003688888
Effects of rivastigmine on common symptomatology of Alzheimer’s disease (EXPLORE)
Serge Gauthier (2010)
10.1016/0014-4886(92)90053-S
Biochemical and behavioral recovery in a rodent model of Parkinson's disease following stereotactic implantation of dopamine-containing liposomes
Matthew John During (1992)
10.1016/J.PNEUROBIO.2007.10.003
Disease-modifying drugs and Parkinson's disease
Hervé Allain (2008)
10.1002/JBM.B.31000
Neural tissue engineering of the CNS using hydrogels.
David R Nisbet (2008)
10.1016/j.brainres.2007.05.055
Attenuation of β-amyloid-induced toxicity by sialic-acid-conjugated dendrimers: Role of sialic acid attachment
Dhara A. Patel (2007)
10.1016/j.surneu.2004.06.008
Nanotechnology approaches for the regeneration and neuroprotection of the central nervous system.
Gabriel Almeida Silva (2005)
10.1016/j.ijbiomac.2015.08.006
Recent advancement of gelatin nanoparticles in drug and vaccine delivery.
Nityananda Sahoo (2015)
10.4049/jimmunol.179.1.665
Fullerene Nanomaterials Inhibit the Allergic Response1
John J. Ryan (2007)
10.1016/j.solidstatesciences.2006.04.016
Influence of superficial organic modification of MCM-41 matrices on drug delivery rate
Patricia Horcajada (2006)
10.1002/CPLU.201402054
Controlling the Surface Chemistry of Multiwalled Carbon Nanotubes for the Production of Highly Efficient and Stable Laccase‐Based Biocatalysts
Cláudia Gomes Silva (2014)
10.1016/j.biomaterials.2014.03.065
Gold nanoshells-mediated bimodal photodynamic and photothermal cancer treatment using ultra-low doses of near infra-red light.
Raviraj Vankayala (2014)
Structure , properties and applications of fullerenes
B. C. Yadav (2008)
10.1016/j.neulet.2014.09.042
A novel mitochondrially-targeted apocynin derivative prevents hyposmia and loss of motor function in the leucine-rich repeat kinase 2 (LRRK2R1441G) transgenic mouse model of Parkinson's disease
Brian P. Dranka (2014)
10.1007/s11051-013-1886-9
Facile synthesis and post-processing of eco-friendly, highly conductive copper zinc tin sulphide nanoparticles
Rameez Ahmad (2013)
10.1039/C0JM01237H
Surface functionalization of magnetic mesoporous silica nanoparticles for controlled drug release
Baisong Chang (2010)
10.1016/J.MICROMESO.2009.10.026
Aging behavior of pharmaceutical formulations of itraconazole on SBA-15 ordered mesoporous silica carrier material
Randy Mellaerts (2010)
10.1016/j.jconrel.2011.08.017
Transport of drugs across the blood-brain barrier by nanoparticles.
Stefanie Wohlfart (2012)
10.1007/s13311-011-0069-6
Cell Therapeutics in Parkinson’s Disease
Olle Lindvall (2011)
10.1002/smll.200800841
Core/Shell semiconductor nanocrystals.
Peter Reiss (2009)
10.1039/c5nr06998j
CdSe/ZnS quantum dots as sensors for the local refractive index.
Antoine Aubret (2016)
10.1021/bc0000637
A nonviral DNA delivery system based on surface modified silica-nanoparticles can efficiently transfect cells in vitro.
Carsten Kneuer (2000)
10.1016/j.nbd.2009.07.030
Structure and function of the blood–brain barrier
N Joan Abbott (2010)
Synthesis and characterization of tunable rainbow colored colloidal silver NPs using single-nanoparticle plasmonic microscopy and spectroscopy
T Huang (2010)
10.1212/WNL.0b013e31828726f5
Alzheimer disease in the United States (2010–2050) estimated using the 2010 census
Liesi E. Hebert (2013)
10.1517/17425247.2.6.1059
Advances in the delivery of treatments for Parkinson’s disease
Tom H. Johnston (2005)
10.1007/s00216-006-0314-8
Biosensors based on carbon nanotubes
Kannan Balasubramanian (2006)
10.1002/jbm.a.35446
Albuminated PLGA nanoparticles containing bevacizumab intended for ocular neovascularization treatment.
Reyhaneh Varshochian (2015)
[Transport of drugs across the blood-brain barrier].
Breimer Dd (1998)
10.1016/j.ijpharm.2011.05.046
Treatment of glioblastoma with poly(isohexyl cyanoacrylate) nanoparticles.
Stefanie Wohlfart (2011)
10.3109/1061186X.2011.651726
Nano-sized cationic polymeric magnetic liposomes significantly improves drug delivery to the brain in rats
Ming Zhao (2012)
10.2147/IJN.S30463
Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats
Xinxin Yang (2012)
10.1039/c0nr00903b
Chiral inorganic nanoparticles: origin, optical properties and bioapplications.
Yunsheng Xia (2011)
10.1007/s00381-010-1086-1
Surgical morbidity and mortality of pediatric brain tumors: a single center audit
Femke Neervoort (2010)
10.1016/j.ijpharm.2010.01.012
Nanolipidic particles improve the bioavailability and alpha-secretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimer's disease.
Andy J. Smith (2010)
10.1039/c3nr00178d
In situ preparation of gold nanoparticle-loaded lysozyme-dextran nanogels and applications for cell imaging and drug delivery.
Huanxin Cai (2013)
10.1016/J.CCR.2012.05.012
Neurodegenerative diseases and exposure to the environmental metals Mn, Pb, and Hg
Laurent Charlet (2012)
10.1039/c5nr07681a
Shape control of inorganic nanoparticles from solution.
Zhaohui Wu (2016)
10.1016/j.bbrc.2005.03.228
Nanogel-quantum dot hybrid nanoparticles for live cell imaging.
Urara Hasegawa (2005)
10.1038/nbt870
Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice
Tiziano Barberi (2003)
10.1080/10717540590968855
Solid Lipid Nanoparticles Containing Tamoxifen Characterization and In Vitro Antitumoral Activity
Giacomo Fontana (2005)
10.1016/j.ejps.2009.03.009
Development of curcuminoids loaded poly(butyl) cyanoacrylate nanoparticles: Physicochemical characterization and stability study.
Rohit Mulik (2009)
10.1016/j.parkreldis.2007.11.012
Potential applications of nanotechnologies to Parkinson's disease therapy.
Gurutz Linazasoro (2008)
10.1016/j.tips.2013.07.002
Gold-nanoparticle-based biosensors for detection of enzyme activity.
Eliza Hutter (2013)
10.1016/j.bbrc.2006.04.041
Influence of dendrimer's structure on its activity against amyloid fibril formation.
Barbara Klajnert (2006)
Electron microscopic analysis of nanoparticles delivering thioflavin-T after intrahippocampal injection in mouse: implications for targeting beta-amyloid in Alzheimer's disease.
Wolfgang Härtig (2003)
10.1016/j.addr.2012.08.015
Surface engineering of inorganic nanoparticles for imaging and therapy.
Jutaek Nam (2013)
10.1016/j.ijpharm.2006.10.025
Improved bioavailability of orally administered mifepristone from PLGA nanoparticles.
Weiling He (2007)
10.1016/J.JMU.2014.11.001
Microbubble-enhanced Focused Ultrasound-induced Blood–brain Barrier Opening for Local and Transient Drug Delivery in Central Nervous System Disease
Ching-Hsiang Fan (2014)
Protein drug-loaded polymeric NPs
P Panta (2014)
Sol review: biofunctionalized quantum dots in biology and medicine
S Mazumber (2009)
10.1021/mp2005627
Phosphorus dendrimers affect Alzheimer's (Aβ1-28) peptide and MAP-Tau protein aggregation.
Tomasz Wasiak (2012)
10.1186/1757-4749-6-14
A novel enzyme-linked immunosorbent assay for detection of Escherichia coli O157:H7 using immunomagnetic and beacon gold nanoparticles
Zhiqiang Q. Shen (2014)
10.1016/j.biomaterials.2010.01.011
In-situ immobilization of quantum dots in polysaccharide-based nanogels for integration of optical pH-sensing, tumor cell imaging, and drug delivery.
Weitai Wu (2010)
10.1038/nn1265
Dopamine depletion impairs precursor cell proliferation in Parkinson disease
Günter U. Höglinger (2004)
10.1021/bc060244u
Preparation of poly(ethylene glycol)-attached dendrimers encapsulating photosensitizers for application to photodynamic therapy.
Chie Kojima (2007)
10.1016/j.ijbiomac.2006.07.001
Studies on the oridonin-loaded poly(D,L-lactic acid) nanoparticles in vitro and in vivo.
Jie Fang Xing (2007)
10.3109/03639045.2013.789051
Formulation and characterization of intranasal mucoadhesive nanoparticulates and thermo-reversible gel of levodopa for brain delivery
Sumit Sharma (2014)
10.1016/j.neulet.2006.07.020
Nanoparticle iron chelators: A new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance
Gang Liu (2006)
Conceptualizing nanoscale
T. Tretter (2006)
10.1177/0192623309335059
Translocation Pathway of the Intratracheally Instilled C60 Fullerene from the Lung into the Blood Circulation in the Mouse: Possible Association of Diffusion and Caveolae-mediated Pinocytosis
Misaki Naota (2009)
10.1016/j.colsurfb.2011.01.040
Dual temperature/pH-sensitive drug delivery of poly(N-isopropylacrylamide-co-acrylic acid) nanogels conjugated with doxorubicin for potential application in tumor hyperthermia therapy.
Wei Xiong (2011)
10.1007/s11882-012-0302-3
Immune Response to Nanomaterials: Implications for Medicine and Literature Review
Saad A. Syed (2012)
10.1002/adma.200602043
Carbon Nanotube Field‐Effect‐Transistor‐Based Biosensors
Brett L. Allen (2007)
10.1016/J.BEJ.2015.01.010
Gold nanoparticles biosensor of Brucella spp. genomic DNA: Visual and spectrophotometric detections
Naghmeh Sattarahmady (2015)
On the basic concept of ‘‘nanotechnology’
N. Taniguchi (1974)
10.1063/1.4813094
Linear and nonlinear optical properties of ZnO/ZnS and ZnS/ZnO core shell quantum dots: Effects of shell thickness, impurity, and dielectric environment
Zaiping Zeng (2013)
10.1021/bc700477u
Bioconjugated quantum rods as targeted probes for efficient transmigration across an in vitro blood-brain barrier.
Gaixia Xu (2008)
10.1007/978-3-211-33081-4_62
Trimodal nanoelectrode array for precise deep brain stimulation: prospects of a new technology based on carbon nanofiber arrays.
J. Li (2007)
10.1021/la400859e
Preparation and characterization of liposome-encapsulated plasmid DNA for gene delivery.
Rachel M. Levine (2013)
10.1016/j.jns.2009.09.032
Gene therapy using lactoferrin-modified nanoparticles in a rotenone-induced chronic Parkinson model
Rongqin Huang (2010)
10.1039/c4nr07421a
Biosafety evaluations of well-dispersed mesoporous silica nanoparticles: towards in vivo-relevant conditions.
Tsang-Pai Liu (2015)
10.1016/j.drudis.2010.04.005
Functionalized carbon nanotubes for potential medicinal applications.
Yi Zhang (2010)
10.1002/chem.201403883
Hexameric Mn(II) dendrimer as MRI contrast agent.
Jiang Zhu (2014)
10.1016/j.nano.2011.12.002
Quantitative characterization of the lipid encapsulation of quantum dots for biomedical applications.
Justin F. Galloway (2012)
10.1371/journal.pone.0114601
Protein-Coated Nanoparticles Are Internalized by the Epithelial Cells of the Female Reproductive Tract and Induce Systemic and Mucosal Immune Responses
Savannah E. Howe (2014)
10.1016/S0022-3999(02)00309-4
Depression and immune function: central pathways to morbidity and mortality.
Janice K Kiecolt-Glaser (2002)
10.1021/nl0516862
Nanoparticle-mediated local and remote manipulation of protein aggregation.
Marcelo J Kogan (2006)
10.1016/j.ijdevneu.2005.11.012
Thioflavins released from nanoparticles target fibrillar amyloid β in the hippocampus of APP/PS1 transgenic mice
Thomas Siegemund (2006)
10.1109/TNB.2003.820279
Receptor-mediated targeting of magnetic nanoparticles using insulin as a surface ligand to prevent endocytosis
A.K. Gupta (2003)
10.1038/318162a0
C60: Buckminsterfullerene
Harold W. Kroto (1985)
10.1016/j.envpol.2011.01.018
Detection of fullerenes (C60 and C70) in commercial cosmetics.
Troy M. Benn (2011)
Nanotecnologia: a próxima revolução na agropecuária
H Brandao (2011)
10.1602/neurorx.2.1.108
Drug transport to brain with targeted nanoparticles
J C Olivier (2011)
10.1039/B314481J
Advances toward bioapplications of carbon nanotubes
Yi Lin (2004)
10.1039/C0JM03232H
Controlled loading of superparamagnetic nanoparticles in fluorescent nanogels as effective T2-weighted MRI contrast agents
Eugene Shi Guang Choo (2011)
10.1134/S0036029511040057
Structural Classification of Nanomaterials
Alex M. Glezer (2011)
10.1039/c3cp54145b
Sensitized solar cells with colloidal PbS-CdS core-shell quantum dots.
Lai-Hung Lai (2014)
10.1016/j.bbagen.2006.08.008
Attenuation of beta-amyloid induced toxicity by sialic acid-conjugated dendrimeric polymers.
Dhara A. Patel (2006)
10.3233/JAD-2008-13210
Nanotechnology solutions for Alzheimer's disease: advances in research tools, diagnostic methods and therapeutic agents.
Amir Nazem (2008)
10.1016/j.jconrel.2009.03.002
Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones.
Anja Zensi (2009)
10.1002/chem.201500578
Mesoporous-Silica-Functionalized Nanoparticles for Drug Delivery.
Simon Giret (2015)
10.1002/smll.200500175
Vertically aligned carbon nanofiber arrays: an advance toward electrical-neural interfaces.
Thuy-Duong Barbara Nguyen-Vu (2006)
10.1002/smll.200901789
Mesoporous silica nanoparticles for intracellular controlled drug delivery.
Juan L Vivero-Escoto (2010)
10.1523/JNEUROSCI.4859-05.2006
Dopaminergic Substantia Nigra Neurons Project Topographically Organized to the Subventricular Zone and Stimulate Precursor Cell Proliferation in Aged Primates
Nils Freundlieb (2006)
10.1111/epi.12895
ICD coding for epilepsy: past, present, and future--a report by the International League Against Epilepsy Task Force on ICD codes in epilepsy.
Nathalie Jette (2015)
10.1172/JCI33464
Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis.
Alexandre Salgado Basso (2008)
10.1038/nature00900
Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease
Jong-Hoon Kim (2002)
10.1016/j.biomaterials.2010.06.030
Core-shell hybrid nanogels for integration of optical temperature-sensing, targeted tumor cell imaging, and combined chemo-photothermal treatment.
Weitai Wu (2010)
10.1016/j.jconrel.2007.01.016
Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo.
Gayatri Mittal (2007)
10.1016/j.vaccine.2013.11.069
Nanoparticle vaccines.
Liang Zhao (2014)
10.1103/PhysRevA.13.2287
Size effect on the melting temperature of gold particles
Pa Buffat (1976)
10.1109/MNANO.2014.2355277
Inorganic Nanoparticles: Engineering for Biomedical Applications
Jin Zhang (2014)
10.1016/j.biomaterials.2014.04.041
Engineered protein nanoparticles for in vivo tumor detection.
Keum-Young Ahn (2014)
10.1515/cclm.2011.732
Gold nanoparticles in the clinical laboratory: principles of preparation and applications
Hassan Mohamed El-Said Azzazy (2011)
10.1039/c1cs15166e
Gold nanoparticles in biomedical applications: recent advances and perspectives.
Lev A Dykman (2012)
10.1039/c1ob05067b
Fullerenolates: metallated polyhydroxylated fullerenes with potent anti-amyloid activity.
Alexander G Bobylev (2011)
10.1016/J.MSER.2010.06.013
Surface nano-functionalization of biomaterials
Xuanyong Liu (2010)
10.1016/j.ijpharm.2010.10.012
Nano spray drying: a novel method for preparing protein nanoparticles for protein therapy.
Sie Huey Lee (2011)
10.1016/j.neuroscience.2010.05.031
Neuroprotective mechanism conferred by 17beta-estradiol on the biochemical basis of Alzheimer's disease
Zareen Amtul (2010)
10.1016/j.jcis.2012.03.014
A simple approach to prepare monodisperse mesoporous silica nanospheres with adjustable sizes.
Meihua Yu (2012)
10.1111/j.1460-9568.2011.07613.x
Neurodegenerative disease and adult neurogenesis.
Beate Winner (2011)
10.1016/j.jalz.2011.03.005
The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
Guy M. McKhann (2011)
10.1080/00222338208062416
Concepts of Trapping Topologically by Shell Molecules
Mieczysław Maciejewski (1982)
10.1016/j.neuroscience.2006.09.017
Human embryonic stem cells: Long term stability, absence of senescence and a potential cell source for neural replacement
Xianmin Zeng (2007)
10.1046/j.1471-4159.1997.69041746.x
Lipid binding to amyloid beta-peptide aggregates: preferential binding of cholesterol as compared with phosphatidylcholine and fatty acids.
Nicolai A. Avdulov (1997)
10.1002/wnan.59
Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease.
Padmakar V. Kulkarni (2010)
Detection of fullerenes (C 60 and C 70) in commercial cosmetics
Troy M. Benn (2011)
10.1070/QE1998v028n03ABEH001188
Quantum dot laser
Anatolii N. Oraevsky (1998)
10.1016/j.biomaterials.2011.08.082
Multi-functional core-shell hybrid nanogels for pH-dependent magnetic manipulation, fluorescent pH-sensing, and drug delivery.
Weitai Wu (2011)
10.1007/s10895-008-0367-5
Luminescent Detection of ATP in Aqueous Solution Using Positively Charged CdSe–ZnS Quantum Dots
John F. Callan (2008)
10.1039/B711141J
Photodynamic therapy with fullerenes.
Pawel Mróz (2007)
10.1021/ja807220u
Surface functionalization of nanomaterials with dendritic groups: toward enhanced binding to biological targets.
Amanda L. Martin (2009)
10.1016/0140-6736(91)92978-B
Intramuscular desferrioxamine in patients with Alzheimer's disease
D. R. Crapper Mclachlan (1991)
10.1016/j.nano.2011.08.006
Nanoparticles in the treatment and diagnosis of neurological disorders: untamed dragon with fire power to heal.
J. R. Kanwar (2012)
10.1007/s00604-012-0904-4
Electrochemical sensing of hydrogen peroxide using metal nanoparticles: a review
Shihong Chen (2012)
10.1007/s10853-011-5938-1
A cellular level biocompatibility and biosafety evaluation of mesoporous SiO2-based nanocomposite with lanthanum species
Wusheng Guo (2011)
10.1002/anie.200460437
Functionalized carbon nanotubes for plasmid DNA gene delivery.
Davide Pantarotto (2004)
10.2174/1567205053585954
C-1073 (mifepristone) in the adjunctive treatment of Alzheimer's disease.
Charles Debattista (2005)
10.1523/JNEUROSCI.0837-06.2006
Dopamine D3 Receptor Agonist Delivery to a Model of Parkinson's Disease Restores the Nigrostriatal Pathway and Improves Locomotor Behavior
Jackalina M Van Kampen (2006)
10.1146/annurev-anchem-060908-155136
Semiconductor quantum dots for bioimaging and biodiagnostic applications.
Brad A. Kairdolf (2013)
10.2174/0929867311302010013
Molecular properties of lysine dendrimers and their interactions with Aβ-peptides and neuronal cells.
Igor Neelov (2013)
10.1016/j.ejps.2012.12.007
Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model.
Shadab Md (2013)
10.1038/nm.2220
Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future
Anthony E. Lang (2010)
10.1159/000255578
Safety and Tolerability of Donepezil, Rivastigmine and Galantamine for Patients with Alzheimer’s Disease: Systematic Review of the ‘Real-World’ Evidence
Ian Lockhart (2009)
10.1002/CBIC.200700338
Branched KLVFF tetramers strongly potentiate inhibition of beta-amyloid aggregation.
Sidhartha M. Chafekar (2007)
10.1021/cr300441a
Uptake of engineered gold nanoparticles into mammalian cells.
Lev A Dykman (2014)
10.1007/BF01977618
Drug transport across the blood-brain barrier
J. B. M. M. Bree (2005)
10.1016/j.drudis.2011.03.004
Design and engineering of nanogels for cancer treatment.
Murali M Yallapu (2011)
10.1016/j.ijpharm.2009.08.021
Design, biometric simulation and optimization of a nano-enabled scaffold device for enhanced delivery of dopamine to the brain.
Samantha Pillay (2009)
10.1093/brain/awh374
Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors.
Thomas Carlsson (2005)
10.1016/S0168-3659(00)00339-4
Biodegradable polymeric nanoparticles as drug delivery devices.
Kumaresh S. Soppimath (2001)
10.1212/01.WNL.0000149637.70961.4C
Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease
Dag Nyholm (2005)
10.1016/J.COCIS.2014.07.002
Biopolymer-based nanoparticles and microparticles: Fabrication, characterization, and application
Iris J. Joye (2014)
THE ENGINE OF CREATION
J. Knight (1999)
Compacted DNA nanoparticle gene transfer of GDNF Adaya et al. 983 to the rat striatum enhances the survival of grafted fetal dopamine
DM Yurek (2009)
10.1186/1556-276X-9-498
Ferromagnetism and optical properties of La1 − xx
Yutana Janbutrach (2014)
10.1186/1556-276X-9-1
Prepare dispersed CIS nano-scale particles and spray coating CIS absorber layers using nano-scale precursors
Jian-Chiun Liou (2014)
10.1002/jgm.1361
Neuroprotection in a 6-hydroxydopamine-lesioned Parkinson model using lactoferrin-modified nanoparticles.
Rongqin Huang (2009)
10.3906/KIM-1409-56
Improvement of solubility of celecoxib by inclusion in MCM-41 mesoporous silica: drug loading and release
Şahika Günaydin (2015)
10.1016/j.biomaterials.2010.11.068
N-acetylgalactosamine-functionalized dendrimers as hepatic cancer cell-targeted carriers.
Scott H Medina (2011)
10.1016/j.taap.2011.05.006
Association between environmental exposure to pesticides and neurodegenerative diseases.
Tesifón Parrón (2011)
10.4172/2150-3494.1000072
Validated and Sensitive Spectrophotometric Method for the Determination of Amitriptyline Hydrochloride
Hosakere D Revanasiddappa (2013)
10.1016/j.msec.2015.12.035
Preparation, characterization and toxicological investigation of copper loaded chitosan nanoparticles in human embryonic kidney HEK-293 cells.
Divya Arora (2016)
10.1039/c1nr11271f
Curcumin loaded chitin nanogels for skin cancer treatment via the transdermal route.
Sabitha Mangalathillam (2012)
10.1021/nn200365a
The shape effect of mesoporous silica nanoparticles on biodistribution, clearance, and biocompatibility in vivo.
Xinglu Huang (2011)
10.1002/JGM.1152
Intravenous glial-derived neurotrophic factor gene therapy of experimental Parkinson's disease with Trojan horse liposomes and a tyrosine hydroxylase promoter.
Chun-fang Xia (2008)
10.1007/s11095-008-9688-y
Development of a Smart Nano-vehicle to Target Cerebrovascular Amyloid Deposits and Brain Parenchymal Plaques Observed in Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Edward Agyare (2008)
10.1016/j.biomaterials.2012.02.004
A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas.
Yan Li (2012)
10.1001/archneur.58.9.1395
Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease.
Joseph L. Price (2001)
10.1002/1531-8257(200001)15:1<9::AID-MDS1004>3.0.CO;2-5
Viral vectors in the treatment of Parkinson's disease.
D. S. Latchman (2000)
10.1039/b502142c
Size matters: why nanomaterials are different.
Emil Roduner (2006)
10.1166/jnn.2003.077
Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain.
Joerg Prof Dr Kreuter (2004)
10.1080/10611860903112842
Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles
K. B. Kurakhmaeva (2009)
10.1093/ajcn/71.2.630s
Vitamin E and Alzheimer disease: the basis for additional clinical trials.
M. Grundman (2000)
10.1093/brain/awl280
Therapeutic approaches to Alzheimer's disease.
Hans-Wolfgang Klafki (2006)
10.4236/JBISE.2014.710082
Protein Drug-Loaded Polymeric Nanoparticles
Prasamsha Panta (2014)
10.1002/smll.201301093
Multifunctional upconversion mesoporous silica nanostructures for dual modal imaging and in vivo drug delivery.
Chunxia Li (2013)
10.1021/nl404727m
A universal law for cell uptake of one-dimensional nanomaterials.
Xin Yi (2014)
10.1016/j.jconrel.2011.02.022
Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration.
Ziyi Wen (2011)
10.1016/J.CARBPOL.2011.11.033
Controlling the thickness of polymeric shell on magnetic nanoparticles loaded with doxorubicin for targeted delivery and MRI contrast agent
Sumanta Kumar Sahu (2012)
10.1039/c2cs15309b
Endocytosis at the nanoscale.
Irene Cantón (2012)
10.1039/c1nr11188d
Gold nanoparticles: preparation, properties, and applications in bionanotechnology.
Yi-Cheun Yeh (2012)
10.1208/s12249-012-9767-6
Ligustrazine Phosphate Ethosomes for Treatment of Alzheimer’s Disease, In Vitro and in Animal Model Studies
Jun Shi (2012)
10.1039/c1cs15188f
Toxicity of nanomaterials.
Samira Sharifi (2012)
10.1186/1556-276X-8-4
Synthesis and characterization of NIR-responsive Aurod@pNIPAAm-PEGMA nanogels as vehicles for delivery of photodynamic therapy agents
Ting Shang (2013)
10.1007/s11051-012-0964-8
Synthesis optimization and characterization of chitosan-coated iron oxide nanoparticles produced for biomedical applications
Gozde Unsoy (2012)
10.1016/j.ijpharm.2011.10.039
Oil based nanocarrier system for transdermal delivery of ropinirole: a mechanistic, pharmacokinetic and biochemical investigation.
Adnan Azeem (2012)
10.3109/10717544.2013.801051
Biocompatibility, absorption and safety of protein nanoparticle-based delivery of doxorubicin through oral administration in rats
Kishore Golla (2013)
10.1016/j.nano.2010.04.001
Why do we have so many definitions for nanoscience and nanotechnology?
Lajos P. Balogh (2010)
10.1016/j.jneumeth.2007.06.011
ORMOSIL nanoparticles as a non-viral gene delivery vector for modeling polyglutamine induced brain pathology
Ilona Klejbor (2007)
10.1016/S0896-6273(01)00317-8
Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice
R. Cherny (2001)
10.1126/scitranslmed.3002369
Alzheimer’s Disease: The Challenge of the Second Century
David M. Holtzman (2011)
10.1016/j.nbd.2009.07.028
Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases
Reinhard Gabathuler (2010)
10.1088/0957-4484/17/10/005
Synthesis and characterization of water-soluble multiwalled carbon nanotubes grafted by a thermoresponsive polymer.
Guoyong Xu (2006)
10.1126/science.1120027
Probing Cellular Chemistry in Biological Systems with Microelectrodes
R Mark Wightman (2006)
10.1016/S0140-6736(09)60492-X
Parkinson's disease
Andrew J. Lees (2006)
10.1503/cmaj.1060168
Use of memantine to treat Alzheimer's disease
Serge Gauthier (2006)
10.1016/j.actbio.2009.01.010
Novel mesoporous silica-based antibiotic releasing scaffold for bone repair.
Xuetao Shi (2009)
10.1016/J.SURFREP.2014.07.001
Synthesis and surface functionalization of silica nanoparticles for nanomedicine.
Alexander Liberman (2014)
10.1016/j.ijpharm.2015.05.032
Doxorubicin loaded magnetic gold nanoparticles for in vivo targeted drug delivery.
Nihal Saad Elbialy (2015)
10.3109/10717544.2013.871600
Development of etoposide-loaded bovine serum albumin nanosuspensions for parenteral delivery
Zhonglan Wang (2015)
10.1523/JNEUROSCI.19-04-01284.1999
Distinct Mechanisms Underlie Neurotoxin-Mediated Cell Death in Cultured Dopaminergic Neurons
Julie Lotharius (1999)
10.1038/nnano.2012.71
Emissive ZnO-graphene quantum dots for white-light-emitting diodes.
Dong Ick Son (2012)
10.1002/jbm.a.35384
Effects of physicochemical properties of nanomaterials on their toxicity.
Xiaoming Li (2015)
10.1016/J.ICA.2013.07.009
PAMAM dendrimers functionalized with ruthenium nitrosyl as nitric oxide carriers
Antonio C Roveda (2014)
10.1021/nl2011627
"Nanohybrids" based on pH-responsive hydrogels and inorganic nanoparticles for drug delivery and sensor applications.
Andreas Riedinger (2011)
10.12968/HMED.2011.72.11.628
Morbidity and mortality in schizophrenia.
Am Lwin (2011)
10.1016/J.JARE.2010.02.002
Gold nanoparticles: Optical properties and implementations in cancer diagnosis and photothermal therapy
Xiaohua Huang (2010)
10.1016/j.ejps.2009.07.008
Dendrimers: emerging polymers for drug-delivery systems.
Basavaraj K. Nanjwade (2009)
10.1016/J.APSUSC.2008.07.035
Application of core–shell PEGylated CdS/Cd(OH)2 quantum dots as biolabels of Trypanosoma cruzi parasites
Claudilene Ribeiro Chaves (2008)
10.1517/17425247.2015.1041374
Nanomedicine and neurodegenerative disorders: so close yet so far
Giovanni Tosi (2015)
Engineered protein NPs for in vivo tumor detection
KY Ahn (2014)
10.1016/j.matdes.2006.09.022
CARBON NANOTUBE REINFORCED COMPOSITES: POTENTIAL AND CURRENT CHALLENGES
Amal M. K. Esawi (2007)
10.1016/j.colsurfa.2004.06.016
Photoluminescence depending on the ZnS shell thickness of CdS/ZnS core-shell semiconductor nanoparticles
Alexandre Loukanov (2004)
SOLID LIPID NANOPARTICLES AS NOVEL DRUG DELIVERY SYSTEM: AN OVERVIEW
Abhish Bhagwan Jadhav (2015)
10.1002/adma.201301947
25th anniversary article: Colloidal quantum dot materials and devices: a quarter-century of advances.
Jin Young Kim (2013)
10.1039/b410943k
Biomedical applications of functionalised carbon nanotubes.
Alberto Bianco (2005)
10.1002/cphc.200900159
One-pot fabrication of high-quality InP/ZnS (core/shell) quantum dots and their application to cellular imaging.
Sahid Hussain (2009)
10.3389/fphar.2015.00286
Advances and Challenges of Liposome Assisted Drug Delivery
Lisa Sercombe (2015)
10.1186/1556-276X-9-393
Carbon nanotubes: properties, synthesis, purification, and medical applications
Ali Eatemadi (2014)
10.1016/j.ab.2005.07.037
DNA biosensor based on chitosan film doped with carbon nanotubes.
Jia Li (2005)
10.1016/S0014-5793(96)01504-9
The interaction between Alzheimer amyloid beta(1-40) peptide and ganglioside GM1-containing membranes.
L P Choo-Smith (1997)
10.1016/J.NANTOD.2015.06.006
Nanoparticle Uptake: The Phagocyte Problem.
Heather Herd Gustafson (2015)
10.1021/nn501292z
Precision nanomedicine in neurodegenerative diseases.
Meir Goldsmith (2014)
10.1074/jbc.272.37.22987
Acceleration of Amyloid Fibril Formation by Specific Binding of Aβ-(1–40) Peptide to Ganglioside-containing Membrane Vesicles*
L P Choo-Smith (1997)
10.1111/j.1749-6632.2009.05108.x
Advances in the treatment of neurodegenerative disorders employing nanotechnology.
Girish Modi (2010)
10.1016/j.jconrel.2012.05.046
In vivo biodistribution and pharmacokinetics of silica nanoparticles as a function of geometry, porosity and surface characteristics.
Tian Yu (2012)
10.1166/JNN.2012.5709
Fullerene C60 prevents neurotoxicity induced by intrahippocampal microinjection of amyloid-beta peptide.
Evgeniya Makarova (2012)
10.1007/s13346-012-0088-9
Engineering solid lipid nanoparticles for improved drug delivery: promises and challenges of translational research
Dinesh Kumar Mishra (2012)
10.1016/j.ejpb.2010.07.007
Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies.
Shrinidh A Joshi (2010)
10.1007/s12045-011-0109-x
There’s plenty of room at the bottom
Richard Phillips Feynman (1999)
10.1021/ja200120k
Large-scale synthesis of bioinert tantalum oxide nanoparticles for X-ray computed tomography imaging and bimodal image-guided sentinel lymph node mapping.
Myoung Hwan Oh (2011)
10.1016/j.arr.2010.08.006
Ageing and neurodegenerative diseases
Chia-wei Hung (2010)
10.1177/0333102410373159
Co-morbidity of migraine with somatic disease in a large population-based study
Han Q. Le (2011)



This paper is referenced by
10.1007/978-3-319-92483-0_1
Biomaterials and Biological Materials
Hermann Ehrlich (2019)
10.1007/978-981-13-0950-2_17
Biomaterials Developments for Brain Tissue Engineering.
Eduarda P Oliveira (2018)
10.3390/ijms21093243
Biomaterials in Neurodegenerative Disorders: A Promising Therapeutic Approach
Matteo Bordoni (2020)
10.5897/AJPP2019.5008
Nanotechnology: A non-invasive diagnosis and therapeutic tool for brain disorders
Amit Alexander (2019)
10.1016/j.mtbio.2020.100055
Advances in nanotechnology-based strategies for the treatments of amyotrophic lateral sclerosis
Guoying Wang (2020)
10.1007/978-3-030-30930-5_11
Nanocarrier-Mediated Drug Delivery Systems for Neurodegenerative Diseases
Sathika G. G. Arachchige (2019)
10.1155/2018/3407375
Metallic Nanoantioxidants as Potential Therapeutics for Type 2 Diabetes: A Hypothetical Background and Translational Perspectives
Oleh Lushchak (2018)
on Treatment for Neurodegenerative disease with the help of Nanosciences
Syed Tazib Rahaman (2018)
10.3390/molecules25092193
Therapeutic Nanoparticles and Their Targeted Delivery Applications
Abuzer Alp Yetisgin (2020)
10.1016/j.jconrel.2018.12.036
Micro- and nanotechnology approaches to improve Parkinson's disease therapy.
Pablo Vicente Torres-Ortega (2019)
10.3389/fnins.2017.00476
Improving the Delivery of SOD1 Antisense Oligonucleotides to Motor Neurons Using Calcium Phosphate-Lipid Nanoparticles
Li-Yu Chen (2017)
10.3389/fnins.2018.00740
The Dual Role of Hepcidin in Brain Iron Load and Inflammation
Driton Vela (2018)
10.3389/fneur.2020.00344
Tissue Engineering and Biomaterial Strategies to Elicit Endogenous Neuronal Replacement in the Brain
Erin M. Purvis (2020)
10.1016/j.colsurfb.2019.110426
Anti-amyloid activities of three different types of water-soluble fullerene derivatives.
Alexander G Bobylev (2019)
10.1007/978-3-030-30930-5_1
Neurodegenerative Diseases: The Real Problem and Nanobiotechnological Solutions
Mahendra Rai (2019)
10.1007/s11357-019-00116-9
Nanodelivery of phytobioactive compounds for treating aging-associated disorders
Oleh Lushchak (2019)
Semantic Scholar Logo Some data provided by SemanticScholar